Product Name :
NL-1
Description:
NL-1 is a mitoNEET inhibitor with antileukemic effect. NL-1 inhibits REH and REH/Ara-C cells growth with IC50s of 47.35 µM and 56.26 µM, respectively. NL-1-mediated death in leukemic cells requires the activation of the autophagic pathway.
CAS:
188532-26-5
Molecular Weight:
335.46
Formula:
C18H25NO3S
Chemical Name:
5-[(3,5-di-tert-butyl-4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione
Smiles :
CC(C)(C)C1=CC(CC2SC(=O)NC2=O)=CC(=C1O)C(C)(C)C
InChiKey:
QDYYSPGKYXWGSL-UHFFFAOYSA-N
InChi :
InChI=1S/C18H25NO3S/c1-17(2,3)11-7-10(8-12(14(11)20)18(4,5)6)9-13-15(21)19-16(22)23-13/h7-8,13,20H,9H2,1-6H3,(H,19,21,22)
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine} web|{1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine} Endogenous Metabolite|{1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine} Purity & Documentation|{1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine} Purity|{1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine} custom synthesis|{1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine} Cancer}
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
NL-1 is a mitoNEET inhibitor with antileukemic effect. NL-1 inhibits REH and REH/Ara-C cells growth with IC50s of 47.35 µM and 56.26 µM, respectively. NL-1-mediated death in leukemic cells requires the activation of the autophagic pathway.|Product information|CAS Number: 188532-26-5|Molecular Weight: 335.{{Resibufogenin} web|{Resibufogenin} Protocol|{Resibufogenin} Description|{Resibufogenin} custom synthesis|{Resibufogenin} Epigenetic Reader Domain} 46|Formula: C18H25NO3S|Chemical Name: 5-[(3,5-di-tert-butyl-4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione|Smiles: CC(C)(C)C1=CC(CC2SC(=O)NC2=O)=CC(=C1O)C(C)(C)C|InChiKey: QDYYSPGKYXWGSL-UHFFFAOYSA-N|InChi: InChI=1S/C18H25NO3S/c1-17(2,3)11-7-10(8-12(14(11)20)18(4,5)6)9-13-15(21)19-16(22)23-13/h7-8,13,20H,9H2,1-6H3,(H,19,21,22)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 250 mg/mL (745.PMID:25023702 25 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|NL-1 (10-100 μM; 72 hours; REH, REH/Ara-C and ALL cell lines) treatment reduces the number of viable cells in REH, REH/Ara-C and ALL (SUP-B15, TOM-1, JM1, NALM-1, NALM-6, BV-173) cell lines, in a concentration-dependent manner. NL-1 inhibits SUPB15, NALM6 with IC50s of 29.48 µM, 94.26 µM, respectively. TOM1, BV173, NALM1 and JM1 all have similar IC50 values of around 60 µM for NL-1. NL-1 (60 μM; 6 hours; REH, REH/Ara-C cell lines) treatment mediates autophagy, and inhibition of autophagy partially decreased NL-1-induced tumor cell death. NL-1 pretreatment inhibits the chemotactic ability of both REH and REH/Ara-C cells to migrate towards multiple chemoattractants. The cells treated with NL1 shows a dose-dependent decrease in chemotaxis both in the REH and the REH/AraC cells.|In Vivo:|NL-1 (10 mg/kg; intraperitoneal injection; daily; for 5 days; female NSG mice) treatment shows antileukemic activity in an in vivo mouse ALL model.|Products are for research use only. Not for human use.|